Adimab’s antibody technology transfer to Merck Research Laboratories

Adimab’s antibody technology transfer to Merck Research Laboratories
Adimab, the global leader in the discovery and optimisation of fully human monoclonal and bispecific antibodies has entered into an agreement with Merck Research Laboratories to transfer its antibody technology. This technology is believed to support Merck’s pipeline of therapeutic biologic candidates besides its application across its various R&D programs. This technology transfer will enable the Merck researchers to use Adimab’s technology broadly in turn benefitting Adimab with royalties on products from use of this technology, and with upfront and future payments.
How to cite this article:
Hameedunissa Begum Shariff. Adimab’s antibody technology transfer to Merck Research Laboratories . BioLim O-Media. 17 April, 2017. 5(4).
Available from: http://archive.biolim.org/omedia/read/BOMA0244.